VIDEOS :

WES2022 | Yuval Noah Harari and Vanessa Nakate in conversation (3:19)

Why Colleges Are Becoming Cults [Full Series] | Dr. Lyell Asher (15:00 to 43:42

Gary Null Speaking Out at the NYS Assembly Hearing  (25:00)

 

Astragulus found to inhibit breast cancer cell proliferationFujian University of Traditional Medicine (China), September 8, 2022Huang qi (Astragalus) is one of the fundamental herbs in traditional Chinese medicine, with earliest records of its use dating back over 2,000 years ago. Now, a study in BMC Complementary and Alternative Medicine has found that astragulus is also able to prevent the spread of breast cancer cells in the body.

In the study, researchers from the Fujian University of Traditional Chinese Medicine in China looked at how astragulus extract can affect breast cancer cells and the process behind this biological effect. They also looked at the primary isoflavones in the extract, as well as its anti-proliferative activity on three breast cancer lines: MCF-7 (ER+), SK-BR-3 (HER2+) and MDA-MB-231 (triple-negative). They did this by exposing these breast cancer cells to the extract for 48 hours.

In addition, they examined the effect of astragulus extract on phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathways, a primary intracellular signaling pathway that contributes to cell proliferation, growth, migration, metabolism, and apoptosis.

The results of the study showed that the treatment of astragulus exhibited anti-proliferative activity on breast cancer cells. Furthermore, the therapy promoted the death of breast cancer cells. These suggested that it’s ability to inhibit breast cancer cell growth was linked to its ability to inhibit PI3K/Akt/mTOR activity. Moreover, the researchers found that the Huang qi extract contains four types of isoflavones, such as campanulin, ononin, calycosin, and formononetin, which contributed to the inhibitory effect of Huang qi extract on breast cancer cells proliferation.

Vitamin D supplementation could help critically ill patientsUniversity Hospital Würzburg (Germany) September 12 2022.

Findings from a review and meta-analysis reported in Critical Care suggest that providing critically ill patients with vitamin D supplements may improve some clinical outcomes, including survival.

“Upon ICU admission, the majority of patients have significantly reduced 25-hydroxyvitamin D levels, which remain significantly reduced over the entire ICU length of stay,” Johannes Menger and colleagues wrote. “In these patients, significantly reduced vitamin D (25-hydroxyvitamin D) serum levels are frequent and independently associated with higher incidence and severity of sepsis.”

Sixteen randomized, controlled trials that evaluated vitamin D supplementation’s association with mortality were identified.

Vitamin D supplementation was associated with a 22% lower risk of overall mortality in comparison with a placebo or standard care. Among studies that reported 28-day mortality, vitamin D supplementation was associated with a trend toward lower a lower risk. Receiving vitamin D by injection or intravenously had the strongest effect. Patients who received vitamin D spent an average of 3.13 days less in the ICU and 5 fewer days on a ventilator than those who received a placebo.

“The results of this systematic review and meta-analysis suggest that vitamin D supplementation may be associated with reduced overall mortality in critically ill patients,” they concluded.

Natural compound could reduce breast cancer risk in some women

Luteolin may inhibit growth of human breast cancer cells in postmenopausal women taking hormone replacement therapy

University of Missouri-Columbia, September 9, 2022

More than 100 women die from breast cancer every day in the United States. The odds increase in postmenopausal women who have taken a combined estrogen and progestin hormone replacement therapy; these women also have